Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook

Teva Reports Second Quarter 2021 Financial Results

July 28, 2021 7:00 AM EDT

Revenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed: Net revenues of $16.0 - $16.4 billion vs. previous range of $16.4 - $16.8 billion Adjusted EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:... More